<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39239468</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-5549</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Clinical Medicine Insights. Oncology</Title><ISOAbbreviation>Clin Med Insights Oncol</ISOAbbreviation></Journal><ArticleTitle>Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center.</ArticleTitle><Pagination><StartPage>11795549241275665</StartPage><MedlinePgn>11795549241275665</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11795549241275665</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/11795549241275665</ELocationID><Abstract><AbstractText>Zanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice daily (BID) and 320 mg once daily (QD). Although the 160 mg BID regimen was the recommended phase 2 dose and more widely used in clinical trials, both regimens have yielded similar efficacy and safety. Currently, there is a lack of reported clinician experience on zanubrutinib QD versus BID practice patterns. This article provides perspectives on zanubrutinib dosing through interviews with 2 clinical care professionals at the Maryland Oncology Hematology Center, based on their experiences treating patients with Waldenström macroglobulinemia (WM) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Zanubrutinib QD is the preferred regimen for some physicians and pharmacists, as it may improve treatment adherence within weeks after initiation compared with BID dosing. According to the clinician interviews provided in this report, patients have reported positive experiences with QD dosing, including a reduced administration burden in those with complicated polypharmacy. Thus, observations from this single center indicate that the zanubrutinib QD regimen may offer benefits to both patients with WM or CLL/SLL and their clinical care teams and should be considered in patients receiving zanubrutinib.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narang</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8701-6210</Identifier><AffiliationInfo><Affiliation>US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Med Insights Oncol</MedlineTA><NlmUniqueID>101525771</NlmUniqueID><ISSNLinking>1179-5549</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Waldenström macroglobulinemia</Keyword><Keyword MajorTopicYN="N">Zanubrutinib</Keyword><Keyword MajorTopicYN="N">chronic lymphocytic leukemia</Keyword><Keyword MajorTopicYN="N">dosing schedule</Keyword><Keyword MajorTopicYN="N">real-world</Keyword><Keyword MajorTopicYN="N">small lymphocytic lymphoma</Keyword></KeywordList><CoiStatement>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M Narang reports consulting or advisory roles with BeiGene, Bristol Myers Squibb, Celgene, DSI, and Takeda and speakers bureaus with BeiGene, Bristol Myers Squibb, and Takeda, outside the submitted work. C Horn and E Lee have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39239468</ArticleId><ArticleId IdType="pmc">PMC11375653</ArticleId><ArticleId IdType="doi">10.1177/11795549241275665</ArticleId><ArticleId IdType="pii">10.1177_11795549241275665</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shirley M. Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features. Target Oncol. 2022;17:69-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8783859</ArticleId><ArticleId IdType="pubmed">34905129</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Liu Y, Hu N, et al.. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62:7923-7940.</Citation><ArticleIdList><ArticleId IdType="pubmed">31381333</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadman M, Flinn IW, Levy MY, et al.. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10:e35-e45.</Citation><ArticleIdList><ArticleId IdType="pubmed">36400069</ArticleId></ArticleIdList></Reference><Reference><Citation>Brukinsa (zanubrutinib) [package insert (USA)]. San Mateo, CA: BeiGene USA; 2023.</Citation></Reference><Reference><Citation>Brukinsa (zanubrutinib) [summary of product characteristics (EU)]. Ireland: BeiGene Ireland Limited; 2021.</Citation></Reference><Reference><Citation>Gale RP. Chronic lymphocytic leukemia in China. Chin Med J (Engl). 2022;135:883-886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276188</ArticleId><ArticleId IdType="pubmed">34636775</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam CS, Trotman J, Opat S, et al.. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851-859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742923</ArticleId><ArticleId IdType="pubmed">31340982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam CS, Opat S, D’Sa S, et al.. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038-2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596850</ArticleId><ArticleId IdType="pubmed">32731259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JR, Eichhorst B, Hillmen P, et al.. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319-332.</Citation><ArticleIdList><ArticleId IdType="pubmed">36511784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam CS, Brown JR, Kahl BS, et al.. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031-1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">35810754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329-1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">34491123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou YC, Tang Z, Novotny W, et al.. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62:2612-2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">34159878</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Sun M, Qi J, et al.. A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. Br J Haematol. 2022;198:62-72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9321909</ArticleId><ArticleId IdType="pubmed">35383885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam C, Shadman M, Sharman J, et al.. PB1926: efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analyses (abstract). HemaSphere. 2023;7:e70124b70125.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>